Editorial: Women in Head and Neck Cancer 2021

Vermorken J, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S . Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-27. DOI: 10.1056/NEJMoa0802656. View

Burtness B, Harrington K, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7. View

Burtness B, Rischin D, Greil R, Soulieres D, Tahara M, de Castro Jr G . Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol. 2022; 40(21):2321-2332. PMC: 9287281. DOI: 10.1200/JCO.21.02198. View